Table 3

Levels of D-dimer in controls and VTE cases using a cut-off of 2×ULN at baseline and month 12 (D-dimer data set)

Treatment armBaselineMonth 12
ULNControls,
n (%)		VTE cases,
n (%)		Controls,
n (%)		VTE cases,
n (%)
Tofacitinib 5 mg two times per day≥2×ULN
<2×ULN		618 (50)
625 (50)		9 (64)
5 (36)		282 (26)
798 (74)		6 (100)
0 (0)
Tofacitinib 10 mg two times per day*≥2×ULN
<2×ULN		602 (50)
592 (50)		21 (68)
10 (32)		290 (29)
717 (71)		11 (58)
8 (42)
TNFi≥2×ULN
<2×ULN		599 (48)
642 (52)		6 (67)
3 (33)		316 (30)
740 (70)		2 (40)
3 (60)

  • *For patients assigned to receive tofacitinib at a dose of 10 mg two times per day who had their dose reduced to 5 mg two times per day, the data collected after patients had been switched to 5 mg two times per day were counted in the arm receiving 10 mg two times per day.

  • TNFi, tumour necrosis factor inhibitor; ULN, upper limit of normal; VTE, venous thromboembolism.